In real-world clinical practice current status of refractory with topical antifungal drug therapy on onychomycosis and efficacy and safety of fosravuconazole switching treatment: a retrospective study

In real-world clinical practice current status of refractory with topical antifungal drug therapy on onychomycosis and efficacy and safety of fosravuconazole switching treatment: a retrospective study - In real-world clinical practice current status of refractory with topical antifungal drug therapy on onychomycosis and efficacy and safety of fosravuconazole switching treatment: a retrospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048054

Enrollment

Registered

2022-06-14

Start date

2022-03-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Onychomycosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with tinea onychomycosis on either toenail of toe I to toe III at the time of initiation of fosravuconazole therapy 2) Patients who started fosravuconazole treatment between July 28, 2018 and February 28, 2021 after switching from a topical nail antifungal agent

Exclusion criteria

Exclusion criteria: 1) Patients with significant thickening, deformation, or discoloration of the nails due to diseases such as palmoplantar pustulosis psoriasis vulgaris, lichen planus, pachyonychia , subungual tumor, or onychogryphosis 2) Patients who refuse to provide medical information for this study

Design outcomes

Primary

Measure	Time frame
Clinical cure rate at the final data of fosravuconazole treatment	—

Secondary

Measure	Time frame
1) Efficacy assessment at the final data of fosravuconazole treatment 2) Change in clinical cure rate from fosravuconazole initiation to 12, 24, 36, and 48 weeks of treatment and at the final data 3) Days to clinical cure 4) Change in nail involvement ratio from fosravuconazole initiation to 12, 24, 36, and 48 weeks of treatment and at the final data 5) Percentage decrease in involvement ratio from fosravuconazole initiation to 12, 24, 36, and 48 weeks of treatment and at the final data 6) Efficacy assessment of fosravuconazole at 12, 24, 36, and 48 weeks and at the final data	—

Measure

Time frame

1) Efficacy assessment at the final data of fosravuconazole treatment 2) Change in clinical cure rate from fosravuconazole initiation to 12, 24, 36, and 48 weeks of treatment and at the final data 3) Days to clinical cure 4) Change in nail involvement ratio from fosravuconazole initiation to 12, 24, 36, and 48 weeks of treatment and at the final data 5) Percentage decrease in involvement ratio from fosravuconazole initiation to 12, 24, 36, and 48 weeks of treatment and at the final data 6) Efficacy assessment of fosravuconazole at 12, 24, 36, and 48 weeks and at the final data

—

Countries

Japan

Contacts

Public ContactShusuke Tani

Nouvelle Place Inc. Data management group

data_QC@n-place.co.jp03-6680-2525

Outcome results